Literature DB >> 24054867

iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology.

Gopitkumar Shah1, Guangjian Zhang1, Fanghong Chen1, Yanli Cao1, Balaraman Kalyanaraman2, William A See3.   

Abstract

OBJECTIVES: Evidence suggests that oxidative stress occurring as a consequence of inducible nitric oxide synthase/nitric oxide (iNOS/NO) contributes to the biologic effects of bacille Calmette-Guérin (BCG). Objective of this study is to examine iNOS expression, NO production, and the biologic effect of NO on established intermediate end points for the human urothelial carcinoma cell response to BCG.
MATERIALS AND METHODS: Quantitative reverse transcriptase-polymerase chain reaction and real-time measurement of NO was used to assess iNOS and NO production, respectively, in 2 human urothelial carcinoma (UC) cell lines, in response to BCG. The effect of blocking NO production using the specific iNOS inhibitor 1400W was determined for multiple intermediate end points characterizing BCG's direct effects on tumor cell biology. Activation of nuclear factor kappa B and nuclear factor (erythroid-derived 2)-like 2 signaling pathways, transactivation of genes, including p21, CD54, IL6, IL8, CXCL1, CXCL3, CCL20, and cytotoxicity, as measured by vital dye exclusion, lactate dehydrogenase release, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay were measured in response to BCG with and without iNOS inhibition.
RESULTS: Exposure of UC cells to BCG significantly increased both iNOS expression and NO production. Inhibition of iNOS activity with 1400W significantly inhibited BCG's direct biologic effect on UC cells for all of the end points evaluated.
CONCLUSIONS: iNOS expression, NO production, and the associated oxidative stress play a central role in the response of UC cells to BCG exposure. Manipulation of oxidative stress may afford an opportunity to enhance the antitumor effects of BCG.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BCG; Bladder cancer; NO; iNOS

Mesh:

Substances:

Year:  2013        PMID: 24054867      PMCID: PMC5798243          DOI: 10.1016/j.urolonc.2013.06.005

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  25 in total

1.  Nitric oxide synthase gene and protein expression are upregulated by Bacille Calmette-Guérin in the rat bladder.

Authors:  B R Oh; K Nakajima; K Y Ahn; S B Ryu; Y I Park; R Dahiya
Journal:  Eur Urol       Date:  2001-03       Impact factor: 20.096

2.  The effect of intravesical Bacillus Calmette-Guerin instillations on the expression of inducible nitric oxide synthase in humans.

Authors:  Dionisios Mitropoulos; Dimitrios Petsis; Aspasia Kyroudi-Voulgari; Mirsini Kouloukoussa; Anastasios Zervas; Constantinos Dimopoulos
Journal:  Nitric Oxide       Date:  2005-08       Impact factor: 4.427

Review 3.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Authors:  M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer
Journal:  J Urol       Date:  2007-12       Impact factor: 7.450

4.  1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo.

Authors:  E P Garvey; J A Oplinger; E S Furfine; R J Kiff; F Laszlo; B J Whittle; R G Knowles
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

5.  Bacillus Calmette-Guérin induces cellular reactive oxygen species and lipid peroxidation in cancer cells.

Authors:  Juwita N Rahmat; Kesavan Esuvaranathan; Ratha Mahendran
Journal:  Urology       Date:  2012-03-23       Impact factor: 2.649

Review 6.  Inducible nitric oxide synthase and control of intracellular bacterial pathogens.

Authors:  Dipshikha Chakravortty; Michael Hensel
Journal:  Microbes Infect       Date:  2003-06       Impact factor: 2.700

7.  HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guérin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guérin.

Authors:  Guangjian Zhang; Fanghong Chen; Yanli Cao; Jonathan V Amos; Gopit Shah; William A See
Journal:  J Urol       Date:  2013-01-23       Impact factor: 7.450

8.  Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer.

Authors:  Abolfazl Hosseini; Lotta Renström Koskela; Ingrid Ehrén; Miguel Aguilar-Santelises; Allan Sirsjö; N Peter Wiklund
Journal:  Nitric Oxide       Date:  2006-03-06       Impact factor: 4.427

9.  Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma.

Authors:  Judith Arnold; Elizabeth C de Boer; Michael A O'Donnell; Andreas Böhle; Sven Brandau
Journal:  J Immunother       Date:  2004 Mar-Apr       Impact factor: 4.456

10.  Bacille-Calmette Guèrin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1.

Authors:  William A See; Guangjian Zhang; Fanghong Chen; Yanli Cao; Peter Langenstroer; Jay Sandlow
Journal:  BJU Int       Date:  2008-12-22       Impact factor: 5.588

View more
  6 in total

1.  Melittin Constrains the Expression of Identified Key Genes Associated with Bladder Cancer.

Authors:  Zidan Jin; Jie Yao; Nianlin Xie; Libo Cai; Shuai Qi; Zhan Zhang; Bai Li
Journal:  J Immunol Res       Date:  2018-05-03       Impact factor: 4.818

Review 2.  Gasotransmitters in cancer: from pathophysiology to experimental therapy.

Authors:  Csaba Szabo
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

3.  Bacillus Calmette-Guérin induces rapid gene expression changes in human bladder cancer cell lines that may modulate its survival.

Authors:  Juwita N Rahmat; Kesavan Esuvaranathan; Ratha Mahendran
Journal:  Oncol Lett       Date:  2018-04-11       Impact factor: 2.967

4.  The Dependence between Urinary Levels of Angiogenesis Factors, 8-Iso-prostaglandin F2α, ɣ-Synuclein, and Interleukin-13 in Patients with Bladder Cancer: A Pilot Study.

Authors:  Beata Szymańska; Ewa Sawicka; Michał Matuszewski; Janusz Dembowski; Agnieszka Piwowar
Journal:  J Oncol       Date:  2020-12-02       Impact factor: 4.375

Review 5.  Immune escape mechanisms and immunotherapy of urothelial bladder cancer.

Authors:  Zhao Yang; Yinyan Xu; Ying Bi; Nan Zhang; Haifeng Wang; Tianying Xing; Suhang Bai; Zongyi Shen; Faiza Naz; Zichen Zhang; Liqi Yin; Mengran Shi; Luyao Wang; Lei Wang; Shihui Wang; Lida Xu; Xin Su; Song Wu; Changyuan Yu
Journal:  J Clin Transl Res       Date:  2021-07-30

6.  MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model.

Authors:  Nina M G P de Queiroz; Fabio V Marinho; Ana Carolina V S C de Araujo; Julia S Fahel; Sergio C Oliveira
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.